Geode Capital Management’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Geode Capital Management’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-157,464	Closed	-$3.63M	–	4528
2020 Q4	$3.63M	Sell	157,464 -13,061	-8%	-$166K	﹤0.01%	2766
2020 Q3	$1.74M	Buy	170,525 +6,705	+4%	+$90K	﹤0.01%	2947
2020 Q2	$2.44M	Buy	163,820 +8,856	+6%	+$136K	﹤0.01%	2733
2020 Q1	$1.89M	Buy	154,964 +56,199	+57%	+$894K	﹤0.01%	2701
2019 Q4	$1.56M	Buy	98,765 +17,099	+21%	+$218K	﹤0.01%	3110
2019 Q3	$1M	Buy	+81,666	New	+$925K	﹤0.01%	3236

Geode Capital Management's PRVL Position: Q1 2021 in Review

Geode Capital Management sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 157,464 shares — an estimated $3.63M sold.

Geode Capital Management first reported a position in PRVL in Q3 2019 and held it in 6 quarters. The position peaked at $3.63M in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

Geode Capital Management reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Geode Capital Management sold 157,464 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $3.63M.
Geode Capital Management first reported a position in Prevail Therapeutics Inc. Common Stock in Q3 2019 and held it in 6 quarters.
Geode Capital Management's Prevail Therapeutics Inc. Common Stock position peaked at $3.63M in Q4 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Geode Capital Management's 13F filing for Q1 2021, filed 12 May 2021.